UVLRX-THERAPEUTICS
11.11.2015 08:04:15 CET | Business Wire | Press release
UVLrx Therapeutics ™ is pleased to present its intravenous light treatment system at the 5th Annual Pro-Aging Europe Congress , a four-day event highlighting medical therapies that reduce, slow down and even reverse the aging process. Beginning on November 19th , this year’s Congress will attract hundreds of the world’s leading anti-aging and aesthetics physicians.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151110007124/en/
Following the company’s recent CE Mark clearance for the UVLrx Station™ Model UVL1500, UVLrx Therapeutics™ will highlight the clinically-proven benefits of light wavelengths utilized by the UVLrx Treatment System. The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical issues. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body.
Among UVLrx Therapeutics Model UVL1500’s eight indications for use in the EU, the UVLrx™ Treatment System significantly reduces inflammation, the root cause of accelerated aging. It also significantly reduces pain and accelerates post surgical healing, two critical factors associated with many aesthetic procedures.
“We are excited to share our technology at the Congress this year and demonstrate in person how we can contribute to patient care within the field of aesthetics and aging,” says Michael Harter, CEO and president of UVLrx™. “By exhibiting at this event, under the supervision of Dr. Thierry Hertoghe , we have the opportunity to treat the world’s leading anti-aging physicians, which will help them understand firsthand UVLrx’s potential within this growing medical field.”
Ultraviolet Blood Irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion in drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, please visit http://uvlrx.com/ and http://bit.ly/1RLN2zb . Be sure to attend UVLrx’s Therapeutic Workshop at the Pro-Aging Congress featuring Chief Scientist Ryan Maloney on Friday, November 20th from 7:00 p.m. to 9:30 p.m.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx
Therapeutics is dedicated to evidence-based medicine in the field of
light therapy and offers the first intravenous, concurrent delivery of
ultraviolet-A (UVA) and multiple visible light wavelengths for treating
a variety of medical issues. In addition to two Nobel Prizes and
NASA-backed research, hundreds of international clinical trials have
verified the health benefits of UV and other wavelengths of light
utilized in the UVLrx™ Treatment System. For more information, please
visit www.uvlrx.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151110007124/en/
Contact:
Press:
Crier Communications
JP Lincoln, 310-274-1072 ext. 201
jp@crierpr.com
or
Business:
UVLrx
Therapeutics
Rowland Hanson
Rowland@UVLrx.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Shareholders Approve All Annual General Meeting Proposals22.4.2026 17:45:00 CEST | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions. Shareholders approved the election of Harry Kirsch as independent member of the Board of Directors, as well as the election of Samuel du Retail and Delphine Viguier-Hovasse, representatives of L’Oréal, as non-independent members of the Board. In addition, Thomas Ebeling (Chair), Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, Roberto Marques, Sherilyn McCoy and Dr. Flemming Ørnskov were re-elected to the Board. The AGM also approved the company’s 2025 Annual Financial Statements, Non-Financial Report and Compensation Report. Detailed voting results and the official minutes will be published on Galderma's
Altrove and Bloomineral Named Winners of the 2026 Grand Prix ACF AutoTech22.4.2026 15:21:00 CEST | Press release
IoT.Bzh receives the inaugural Industrialization Prize at the 9th edition of the international automotive startup competition Altrove and Bloomineral have been crowned winners of the 2026 Grand Prix ACF AutoTech, the international startup competition recognizing the best of automotive innovation. The ninth edition was held on Wednesday, April 15 at the Automobile Club de France in Paris, where IoT.Bzh also received the first-ever Industrialization Prize. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422236542/en/ Picture of the end of the event with the winners : Bloomineral, Altrove and Iot.Bzh + all the Jury Members from French Automotive OEM and Tier1 Hosted by competition founder Richard de Cabrol and Simon Degiovanni, the evening gathered more than 250 leaders from the automotive, technology, digital, business and media sectors, with attendees joining both on-site and online. Six finalist startups, selected from mor
I/ONX Shatters the Host Tax: New Symphony SixtyFour Architecture Delivers 50% TCO Savings Across AI Inference and Fine-Tuning Lifecycle22.4.2026 15:00:00 CEST | Press release
Eliminating infrastructure overhead of legacy designs, I/ONX debuts a scaled AI inference and fine-tuning stack that cuts power by up to 30kW per rack and reduces cost of rack-scale deployments by up to 70% I/ONX High Performance Compute (HPC), a leading provider of heterogeneous AI systems, today announced the global launch of the Symphony SixtyFour, a high-density platform designed to collapse the physical and economic footprint of AI inference and fine-tuning infrastructure. By supporting up to 64 accelerators on a single node, I/ONX eliminates the redundant Host Tax—the massive overhead in power, hardware, and licensing that negatively impacts ROI in enterprise AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422485327/en/ I/ONX Introduces Symphony SixtyFour: The Host Tax is Over. Save 30-50% on your AI Infrastructure Costs. While inference now accounts for 90% of enterprise AI workloads, enterprises are entirely li
Thales Introduces Imperva for Google Cloud, Bringing Its Enterprise-Grade Application Security Capabilities Directly into Google Cloud22.4.2026 15:00:00 CEST | Press release
New offering eliminates the need to choose between cloud-native performance and advanced security as enterprises scale modern applications Thales today announced the Controlled Availability of Imperva for Google Cloud, bringing the industry's most trusted application security platform directly into Google Cloud. Designed to operate within Google Cloud, the new offering enables organizations to protect web applications and APIs by leveraging Google Cloud’s Service Extension traffic, preserving existing pipelines, integrations, and monitoring workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422746638/en/ ©Thales As enterprises accelerate cloud adoption, development teams increasingly standardize on native cloud services to improve speed and reduce operational complexity. Many security solutions, however, require external routing that introduces latency and friction. At the same time, native cloud security tools oft
ClickHouse Expands Strategic Collaboration with Google Cloud, Bringing Deeper Integration, Cloud Flexibility, and Next-Generation Performance22.4.2026 15:00:00 CEST | Press release
ClickHouse, a leader in real-time analytics, data warehousing, observability, and AI/ML, today at Google Next 26 announced a significant expansion of its strategic collaboration with Google Cloud. The announcement encompasses four major milestones: native integration with Google Cloud Lakehouse, the availability of ClickHouse's Bring Your Own Cloud (BYOC), the migration of ClickHouse Cloud on Google Cloud to Google's custom Arm-based Axion processors, and a new integration between the ClickHouse MCP server and Google Antigravity. These advancements deliver deeper interoperability across the data ecosystem, extend deployment flexibility for security-conscious enterprises, and unlock meaningful gains in query performance and cost efficiency for joint customers worldwide. This expansion builds on ClickHouse's growing presence within the Google Cloud ecosystem, where thousands of data-intensive organizations rely on ClickHouse Cloud to power real-time observability, business intelligence,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom